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Abstract
Background: Quality measures should be subjected to a testing protocol before being used in practice using key
attributes such as acceptability, feasibility and reliability, as well as identifying issues derived from actual
implementation and unintended consequences. We describe the methodologies and results of an indicator testing
protocol (ITP) using data from proposed quality indicators for the United Kingdom Quality and Outcomes
Framework (QOF).
Methods: The indicator testing protocol involved a multi-step and methodological process: 1) The RAND/UCLA
Appropriateness Method, to test clarity and necessity, 2) data extraction from patients’ medical records, to test
technical feasibility and reliability, 3) diaries, to test workload, 4) cost-effectiveness modelling, and 5) semi-
structured interviews, to test acceptability, implementation issues and unintended consequences. Testing was
conducted in a sample of representative family practices in England. These methods were combined into an
overall recommendation for each tested indicator.
Results: Using an indicator testing protocol as part of piloting was seen as a valuable way of testing potential
indicators in ‘real world’ settings. Pilot 1 (October 2009-March 2010) involved thirteen indicators across six clinical
domains and twelve indicators passed the indicator testing protocol. However, the indicator testing protocol
identified a number of implementation issues and unintended consequences that can be rectified or removed
prior to national roll out. A palliative care indicator is used as an exemplar of the value of piloting using a multiple
attribute indicator testing protocol - while technically feasible and reliable, it was unacceptable to practice staff and
raised concerns about potentially causing actual patient harm.
Conclusions: This indicator testing protocol is one example of a protocol that may be useful in assessing potential
quality indicators when adapted to specific country health care settings and may be of use to policy-makers and
researchers worldwide to test the likely effect of implementing indicators prior to roll out. It builds on and codifies
existing literature and other testing protocols to create a field testing methodology that can be used to produce
country specific quality indicators for pay-for-performance or quality improvement schemes.
Background
Quality measures are increasingly used internationally to
measure the quality of health care. In many cases, but
not all, these are used as part of pay-for-performance
schemes [1-4]. Any quality assessment measure must
adhere to certain key attributes [5-12]. These include a
clear definition and purpose, their acceptability to asses-
sors and those being assessed, needs assessment, clinical
feasibility and relevance, sensitivity to change, potential
for improvement, discrimination/variance, technical fea-
sibility and reliability of data extraction, an understanding
of how they will be implemented and validity (including
evidence base and addressing unintended consequences).
Measures must also be 100% under the direct control of
* Correspondence: Stephen.campbell@manchester.ac.uk
1Health Sciences Research Group - Primary Care, University of Manchester,
7
th Floor Williamson Building, Oxford Road, Manchester, M13 9PL. UK
Full list of author information is available at the end of the article
Campbell et al. BMC Family Practice 2011, 12:85
http://www.biomedcentral.com/1471-2296/12/85
© 2011 Campbell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.those being assessed (attribution or controllability) or les-
ser control must be reflected in the assessment. Quality
measures, in their development, implementation and in
the interpretation of the results, should be subjected to a
testing protocol, whereby indicators are assessed against
such attributes.
Testing protocols have been developed, mostly for use in
the United States; for example, the Physician Consortium
for Performance Improvement (PCPI) of the American
Medical Association (AMA) [9] or the National Commit-
t e ef o rQ u a l i t yA s s u r a n c e( N C Q A ) ,w h i c hd e v e l o p st h e
Health Plan Employer Data and Information Set (HEDIS)
[6]. Both the PCPI [9] and NCQA [6] use detailed mea-
surement methodologies and in the case of NCQA, the
subsequent HEDIS measures are used by more than 90
percent of health plans in the United States. Piloting has
also been routinely included as part of Veterans Adminis-
tration indicator development method [13].
In 2004, the United Kingdom government introduced
the Quality and Outcomes Framework (QOF), a pay-for-
performance scheme, which consists of clinical and orga-
nisational quality indicators [8]. The original 2004 QOF
indicators, and all subsequent changes to indicators, were
introduced without piloting. In 2009 a new way of devel-
oping clinical indicators for QOF was introduced, led by
the National Institute for Health and Clinical Excellence
(NICE) [14]. NICE now prioritise areas for clinical quality
indicator development, based on national guidelines as
source material.
The development and piloting of potential QOF indica-
tors is contracted to an independent external contractor,
led by the authors, which has two main roles. Our first
role is to review existing QOF indicators and recommend
whether indicators should remain or be removed or
revised. There has been little work at an international level
on this issue and we have developed and described a set of
underpinning principles for indicator replacement and key
issues that need to be considered by any organization or
country planning to remove indicators from a clinical per-
formance framework [15,16].
Our second role is to develop and pilot new indicators
for potential inclusion in QOF. Prior to 2009, none of the
146 indicators in the original QOF had been piloted.
Practical problems with implementation subsequently
occurred, some of which took up to 6 months to correct
during ‘live QOF’. Since over 1 billion pounds is attached
to achieving these indicators on an annual basis, this is
less than ideal. The advocacy of piloting new indicators
in the UK, is not new [17,18]. Nor is the awareness of the
importance of obtaining baseline data before implemen-
tation [19]. However, prior to 2009 there was no pub-
lished indicator testing protocol for the development and
piloting of quality indicators in the UK.
Objective
This paper describes the multiple stage development and
piloting processes of the indicator testing protocol that
we developed as part of the process of piloting indicators
for the UK QOF. It also presents, the results from the
f i r s tQ O Fp i l o t ,a n ds h o w sh o wt h i st e s t i n gp r o t o c o l
compares to and builds upon existing literature. The test-
ing protocol described is onee x a m p l eo fap r o t o c o lt h a t
may be useful in assessing potential quality indicators
when adapted to specific country health care settings is
and may be of use to policy-makers and researchers
worldwide to test the likely effect of implementing indi-
cators prior to roll out.
Methods
The indicator testing protocol consists of two stages: indi-
cator development and indicator testing (see Figure 1).
Stage 1: Indicator development
Clinical conditions/issues recommended for indicator
development, which are supported by a NICE/SIGN (Scot-
tish Intercollegiate Guidelines Network) guideline, are sug-
gested for development by a NICE Advisory Committee
that sits twice yearly in June and December (http://www.
nice.org.uk/aboutnice/qof/PrimaryCareQOFIndicatorAdvi-
soryCommittee.jsp) (Figure 1). For each suggested area, we
(the external contractor group and authors of this paper)
then develop a set of initial indicator ‘sets’. Each set repre-
sents a coherent group of indicators in the same clinical
domain (e.g. diabetes) that avoid duplication and address
specifically defined aspects of quality of care. The key to
successful indicator development is to precisely define the
meaning and specifications of an indicator so that what is
being assessed is clear and the assessment of quality is
attributable directly to that indicator [5,6,20]. The pre-
sence of such precision of meaning and purpose facilitates
subsequent analyses of other indicator attributes such as
technical feasibility.
We use the RAND/UCLA Appropriateness Method to
rate the initial sets of indicators. This combines available
scientific evidence with the collective judgement of experts
by deriving a consensus opinion from a group, with indivi-
dual opinions aggregated into refined aggregated opinion
[5,21,22]. The aim is to identify indicators that, if imple-
mented, are likely to provide net benefit to patients and
improve patient outcomes. Panel composition is the major
determinant of final ratings [22]. We appoint a 10 member
panel of front line GPs and GPs with a special clinical
interest in the indicator areas under discussion.
The RAND/UCLA Appropriateness Method involves
two rounds of rating, the first conducted by post and the
second at a face-to-face meeting [21]. Panel members are
sent a summary of the evidence and the list of indicators
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for all the terms used. Indicators that go forward to pilot-
ing must adhere to the RAND/UCLA Appropriateness
Method definition of consensus (overall panel median
of 7-9) with agreement (80% of ratings within the 3-
point tertile of the overall median) for both clarity and
necessity [5,21].
Stage 2: Indicator testing
As part of the indicator testing process, mixed meth-
odologies are used to test particular indicator attributes
(Table 1), based on an overall indicator testing protocol
(Appendix 1).
Clarity and necessity: content validity
The ratings from the RAND/UCLA Appropriateness
Method are used for the assessment of the clarity and
necessity of the indicators (proxies for content validity).
Technical feasibility and reliability
The assessments of technical feasibility and reliability are
akin to the NCQA attributes of feasibility and scientific
soundness [6] and the AMA-PCIP attributes of feasibility
and reliability [9] and are carried out in conjunction with
the UK National Health Service Information Centre
(NHSIC). Feasibility relates to evidence about whether
accurate data are available and collectable in current
family practice information systems, and supported by
current methods of data extraction for QOF. The
assessment of reliability focuses on quality assuring repro-
ducibility. The Information Centre writes a specification
for each indicator, detailing how data will be extracted
from patient electronic medical records. Piloting enables
these data extraction rules to be tested and for any errors
to be identified and rectified.
Implementation - workload
Within each participating practice, we ask the staff most
involved in the pilot and the day-to-day engagement with
QOF to complete workload diaries. This enables us to
assess the effort associated with implementing pilot indi-
cators and also feeds in to subsequent cost-effectiveness
analyses. The diaries include sections on the date and
time of activity, which indicator the activity related to,
activity undertaken using a tick box of options (i.e. com-
puter query searching, meetings, clinical appointments
etc), and whether the activityw a ss c h e d u l e do ri n v o l v e d
not doing other planned work. (These diaries are avail-
able on request).
Implementation: sensitivity to change and discrimination/
variance
We extract data from the family practices’ electronic
medical record systems for each indicator using the data
extraction specification rules at the start (baseline) and at
the end of the pilot. Obtaining both sets of data enable
tracking of performance (sensitivity to change) and cost-
effectiveness modelling to be undertaken. Obtaining
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Figure 1 Flow diagram of the Indicator Testing Protocol.
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recommendations about where to set potential payment
thresholds.
Acceptability and implementation
We assess the acceptability and implementation of indica-
tors through semi-structured interviews with doctors,
nurses and administrative staff involved in piloting.
Assessment of issues and barriers arising from implemen-
tation is a key aspect also of the NCQA [6], QUALIFY [7]
and AMA-PCIP [9] testing protocols respectively.
Cost effectiveness
Cost effectiveness considers whether the costs associated
with an indicator are outweighed by the benefits accrued
by the health service. The approach we use to evaluate the
economic implications of indicators addresses two issues.
The first determines whether the activity or intervention is
cost effective and would result in benefits which are
greater than the costs of undertaking the activity. Health
benefits are measured in Quality Adjusted Life Years
(QALYs) [23] which are valued in monetary terms at
£25,000 (€29,071) each. This is the mid-point of the impli-
cit cost effectiveness threshold of £20,000-£30,000
(€23,259 -€34,889) per QALY gained, which has been
adopted by NICE [24]. The net benefit calculation sub-
tracts the delivery costs of implementation and the pay-
ments from the monetarised health benefits: Net benefit =
(monetised benefit - delivery cost) - QOF payment. The
second relates to the level of payments that can be eco-
nomically justified to increase levels of desired activities
whilst retaining net benefits to the health service. This is
done by hypothesising a link with improved patient out-
comes but is possible only where robust evidence to sup-
port the hypothesis was available, which is more likely for
indicators which have a direct therapeutic effect [25]. In
reality, this evidence is often not available.
Indicator piloting: data collection methods and ana-
lyses We have recruited four separate cohorts of 30
representative family practices across England from
t w e l v eP r i m a r yC a r eT r u s t s ,t h ec u r r e n to r g a n i s a t i o n a l
units with the English NHS of approximately 300,000
patients, to pilot the clinical indicators. Each pilot cohort
includes practices with different clinical information sys-
tems, and practices which are nationally representative in
terms of size, QOF achievement and Index of Multiple
Deprivation (IMD). Each cohort of practices pilots indi-
cators for six months on a rolling basis.
Overall recommendations
Based on the evidence obtained from piloting, we make a
recommendation for each indicator on the four key attri-
butes of acceptability, feasibility, reliability and imple-
mentation (Table 1). Evidence for clarity and content
validity are based on the fact that indicators are under-
p i n n e db yaN I C E / S I G Ng u i d e l i n ea n dR A N D / U C L A
Appropriateness Method ratings.
The three potential recommendations from piloting
are:
1) There are no major barriers/risks/issues/
uncertainties.
2) There are some barriers/risks/issues/uncertainties
but these can be addressed before national roll out.
Table 1 Indicator testing protocol feedback form
Attribute Summary of method
Clarity ￿ RAND Appropriateness Method ratings *
Necessity ￿ RAND Appropriateness Method ratings *
Acceptability ￿ Risks, issues, relative impact, and uncertainties (interviews with practice staff)
Feasibility ￿‘ Technically feasiblility’ in current family practice systems and whether supported by current methods of data
extraction for QOF (data extraction in all family practice clinical systems)
Reliability ￿ Reproducible in testing (data extraction: test-retest)
Implementation ￿ Baseline and potential change in baseline;evidence of sensitivity to change (data extraction);
￿ Exception reporting/gaming (interviews with practice staff);
￿ Changes in practice organisation; potential barriers; workload (interviews with practice staff and workload diaries)
￿ Unintended consequences (interviews with practice staff)
Changes to any existing QOF
indicators
￿ Summary of any suggested changes to existing QOF indicators as a result of piloted indicators
Changes in wording of the
indicator(s)
￿ Summary of any suggested changes to indicator wording
Cost effectiveness ￿ Summary of evidence of cost effectiveness (cost-effectiveness modelling)
Overall recommendation 1) no major barriers/risks/issues/uncertainties
2) some barriers/risks/issues/uncertainties but okay
3) major barriers/risks/issues/uncertainties preclude it
Summary feedback table of indicator testing protocol.
*RAND/UCLA Appropriateness Method overall panel rating of ≥ 7 with agreement (80% of panellist’s ratings within the 3-point tertile of the overall median).
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that preclude the indicators from recommendation for
its inclusion in QOF.
We then use these recommendations as the basis for an
overall recommendation (Table 1). These recommenda-
tions are then considered by the NICE Advisory Commit-
tee which makes decisions about which indicators have
passed piloting, these decisions are then validated by
NICE (Figure 1). They will then be submitted subse-
quently for negotiations between the British Medical
Association General Practitioners Committee and NHS
Employers for possible inclusion in QOF. It is at this
stage that the process of assigning points and payments
to tested and validated indicators takes place.
The study had full ethical committee approval (North
West 4 Research Ethics Committee: Liverpool North:
09/H1001/74).
Results
In June 2009 the NICE Advisory Committee recom-
mended six areas for indicator development (http://www.
nice.org.uk/media/F3E/8C/QOFIACMinutesJune2009.pdf)
to be piloted in pilot 1 (October 2009-March 2010):
asthma, dementia, diabetes, myocardial infarction, serious
mental illness and palliative care.
Clarity and necessity: content validity
We rated the clarity and necessity of the indicators
using the RAND/UCLA Appropriateness Method. Thir-
teen indicators were rated clear and necessary and
therefore went forward to piloting (Table 2).
Examples of issues raised for each of these piloted
indicators in terms of the other key attributes of the
testing protocol (technical feasibility and reliability,
acceptability and implementation) and the overall
recommendations for each indicator in pilot 1 are sum-
marised in Table 2.
Technical feasibility and reliability
During the pilot, we found data measurement specifica-
tions relating to the asthma, diabetes and dementia indica-
tors (Table 2). For example, problems were identified for
the asthma indicator in relation to the reliability of extract-
ing data when data for daytime, night-time and activity
limiting symptoms were recorded in the patient’s medical
record on the same or different days.
Implementation - workload
The majority of workload diaries showed that most of the
QOF indicator work was carried out by practice nurses.
The diaries enabled us to quantify how much time was
spent on each component activity including face to face
work with patients and also underpinning administrative
work. The majority of GP time during the piloting
process was spent in team meeting (73%) and in addres-
sing the dementia and palliative care indicators, whereas
the majority of nurse time spent on piloting was spent in
consultations with patients (90%) with asthma, diabetes
or myocardial infarction. The care associated with pilot-
ing the serious mental illness indicators was divided
between the doctors and nurses.
Implementation: sensitivity to change and discrimination/
variance
Data for the myocardial infarction four drugs indicator
(Aspirin, Betablocker, Statin and ACE inhibitor) showed
low levels of achievement at baseline, making it a good
candidate for evidence based quality improvement and
therefore financial incentivization.
Acceptability and implementation
We conducted semi-structured interviews with 57 mem-
bers of staff in 24 family practices: 21 family doctors, 16
practice managers, 12 nurses and eight others (mostly
information technology experts) during April-May 2010.
All participants in Pilot 1 thought that piloting indica-
tors was essential. The value of piloting was seen as
akin to a ‘reality check’, and learning process highlight-
ing potential problems which could then be addressed
prior to the indicator being implemented on a national
level.
Issues raised by piloting
Examples of issues raised by participants as a direct result
of piloting are shown in Table 2. These included identify-
ing indicators with potential harm to patients (e.g. the
palliative care indicator), low numbers of eligible patients
(e.g. dementia, myocardial infarction), and a need for
changes in practice organization such as changes to com-
puter templates and workload implications such as time
to carry out the incentivised aspect of care if not already
routinely provided (e.g. diabetes foot risk assessment). In
addition, participants identified indicators with conflict-
ing hospital and primary care prescribing patterns; for
example, where patients wered i s c h a r g e df r o mh o s p i t a l
after a myocardial infarction with prescriptions for drugs
that differed from the drugs stipulated in the myocardial
infarction indicator.
Cost effectiveness
Cost effectiveness analyses of the piloted indicators
showed that only the myocardial infarction indicators
could be linked directly to health gains, because there
was clear clinical and economic evidence that recom-
mended all patients presenting with an acute myocardial
infarction should be treated, unless contraindications
apply, with an ACE inhibitor, aspirin and beta-blockers
indefinitely [26,27]. However, for the remaining indica-
tors there were insufficient data to make a clear link with
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Clinical
area
Indicator wording Implementation issues raised as a result of
piloting
Recommendations
1 Asthma The percentage of patients with asthma who have
had an asthma review in the previous 15 months that
includes an assessment of asthma control using the 3
Royal College of Physicians questions (control of
daytime, night time and activity limiting symptoms in
the last week.
￿ Technical feasibility: need for revised IT data entry
templates
Acceptability: no
barriers
￿ Administration of questions by phone, post or face
to face
Feasibility: some
barriers
Reliability: some
barriers
Implementation: no
barriers
Overall: some
barriers to address
2 Dementia The percentage of patients with a new diagnosis of
dementia to have FBC, calcium, glucose, renal and
liver function, thyroid function tests, serum vitamin
B12 and folate levels recorded 6 months before or
after entering on to the register
￿ Inconsistency with dementia referral pathways/
referral governance
Acceptability: no
barriers
￿ Variation in practice - QOF danger of standardizing
practice
Feasibility: no
barriers
￿ Low prevalence in some practices (as confirmed by
the pilot)
Reliability: no
barriers
￿ Tests of calcium levels not always routinely done Implementation:
some barriers
Overall: some
barriers to address
but can go forward
3 Diabetes The percentage of patients with diabetes with a
record of testing of foot sensation using a 10 g
monofilament or vibration (using biothesiometer or
calibrated tuning fork), within the preceding 15
months
￿ Changes required to data entry diabetes templates
where not already included
Acceptability: no
barriers
￿ Education or training of nurses in some practices. Feasibility: no
barriers
Reliability: no
barriers
Implementation: no
barriers
Overall: no barriers
4 Diabetes The percentage of patients with diabetes with a
record of a foot examination and risk classification: 1)
low risk (normal sensation, palpable pulses), 2)
increased risk (neuropathy or absent pulses), 3) high
risk (neuropathy or absent pulses plus deformity or
skin changes or previous ulcer) or 4) ulcerated foot
within the preceding 15 months
￿ Changes required to data entry diabetes templates
where not already included
Acceptability: no
barriers
￿ Education or training of nurses in some practices. Feasibility: no
barriers
￿ Routine data recording Reliability: no
barriers
￿ Workload implications for practice staff Implementation:
some barriers
￿ Attribution problems in terms of payments attached
to QOF if performed outside the practice
Overall: some
barriers to address
but can go forward
￿ Time taken to perform
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5 Myocardial
Infarction
The percentage of patients with a history of
myocardial infarction (from 1 April 2011 {from 1
October 2009 for the purposes of piloting} currently
treated with an ACE inhibitor, aspirin or an alternative
anti-platelet therapy, beta-blocker and statin (unless a
contraindication or side effects are recorded)
Implementation issues: Acceptability: some
barriers
￿ Problems of attribution/hospital led prescribing Feasibility: no
barriers
￿ PCT formulas/guidance/pharmacy advisors content
and advice is contrary to NICE guidelines
Reliability: no
barriers
MI was the only area for which there is useable cost-
effectiveness data
Implementation:
some barriers
Overall: some
barriers to address
but can go forward
6 Myocardial
Infarction
The percentage of patients with a history of
myocardial infarction who have a record of
intolerance or allergy to an ACE inhibitor who are
currently treated with an ARB (unless a
contraindication or side effects are recorded)
￿ Conflicts with variations in local guidance (in some
areas PCT stipulates trying 3 ACEs before an ARB, in
others ARB is front line treatment)
Acceptability: some
barriers
￿ Variation in percentage of patients on ARB Feasibility: no
barriers
￿ Problems of attribution/hospital led prescribing Reliability: no
barriers
￿ Variations in local procedures in i.e. PCT formulas/
guidance/pharmacy advisors
Implementation:
some barriers
￿ Private initiated prescribing effects % of patients on
ARB
Overall: some
barriers to address
but can go forward
MI is the only area for which there is useable cost-
effectiveness data
7 Serious
Mental
Illness
The percentage of patients with schizophrenia, bipolar
affective disorder and other psychoses who have a
record of alcohol consumption in the preceding 15
months
￿ Seldom heard group, whom often consult
opportunistically. Difficulty getting patients to come
back in
Acceptability: some
barriers
Feasibility: no
barriers
Reliability: no
barriers
Implementation:
some barriers
8 Serious
Mental
Illness
The percentage of patients with schizophrenia, bipolar
affective disorder and other psychoses who have a
record of BMI in the preceding 15 months
￿ Low levels of cervical screening Overall: some
barriers to address
but can go forward
9 Serious
Mental
Illness
The percentage of patients with schizophrenia, bipolar
affective disorder and other psychoses who have a
record of blood pressure in the preceding 15 months
￿ Perceived clinical irrelevance to younger patients re.
annual cholesterol, BP, HBA1c/glucose check: these
are not routinely done in all practices for all patients
on the current register
10 Serious
Mental
Illness
The percentage of patients with schizophrenia, bipolar
affective disorder and other psychoses who have a
record of total cholesterol: hdl ratio level in the
preceding 15 months
￿ May create undue focus on individual processes/
indicators in unbundled indicators rather than the
overall physical health of patient “appropriate to their
age, gender and health status”
11 Serious
Mental
Illness
The percentage of patients with schizophrenia, bipolar
affective disorder and other psychoses who have a
record of blood glucose level or HBA1c in the
preceding 15 months
12 Serious
Mental
Illness
The percentage of women aged 25-64 with
schizophrenia, bipolar affective disorder and other
psychoses who have a record of cervical screening
within the last 5 years
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speculative.
Overall recommendations
Based on the evidence obtained from piloting, twelve
indicators passed the indicator testing protocol. The pal-
liative care indicator was recommended for rejection
because, while technically feasible and reliable, it was
unacceptable to practice staff and raised concerns about
upsetting the balance of the doctor patient relationship
and potentially causing actual patient harm due to the
lack of sensitivity of a single isolated target approach.
Piloting also identified a number of implementation
issues and unintended consequences that were subse-
quently rectified or removed prior to national roll out
for the other 5 piloted areas (Table 2).
Discussion
Strengths and limitations of the testing protocol
Strength
In this paper we have described the indicator testing
protocol for assessing potential new QOF indicators
using ‘real time’ examples from the first pilot (October
2009-March 2010). The testing protocol identified a
number of implementation issues and unintended con-
sequences associated with piloted indicators. It demon-
strates the value of piloting as a prerequisite for all
policy-makers prior to introducing indicators as part of
quality assessment. The palliative care indicator is a par-
ticular exemplar of the value of a multiple attribute indi-
cator testing protocol - while technically feasible and
reliable, it had poor acceptability and was rejected for
possible inclusion in QOF.
Limitations
This testing protocol has a number of possible limita-
tions. For example, a cohort of practices involves work-
ing with a maximum of 30 pilot family practices
although these are explicitly selected to be nationally
representative. Second, the piloting period, by necessity
due to tight deadlines in the overall process, is only six
months compared to 12 months in the HEDIS piloting
process. A longer piloting period would for each Pilot
would enable potential changes to bed in and practice
staff more time to engage with the indicators. Third, the
first pilot confirmed that there are currently little data
for cost effectiveness modelling and that cost-benefit
analysis is problematic for process measures because of
the difficulty of linking process to outcome. Fourth, the
piloting process tests the effect of piloted indicators but
it provides no information about how practices respond
to a given financial incentive for a quality indictor as
the process of assigning points and financial rewards for
validated indicators takes place as part of subsequent
negotiations between the NHS Employers and BMA/
GPC.
Implications for practice and policy
In this paper, we have described a testing protocol that
is used to assess potential indicators for the UK QOF.
However, whilst our testing protocol may act as a proto-
type, it is important that each country takes account of
its local context. There are real dangers in directly
translating indicators across settings [28,29]. For exam-
ple, countries such as the United States [2] or Australia
[30] face significant technical and institutional obstacles
in introducing family practice indicator based incentives
schemes because of the availability and comprehensive-
ness of clinical data systems. Moreover, the UK QOF is
underpinned by the fact that patients register with a sin-
gle family practice, unlike many other countries,
enabling practice registers of patients with given condi-
tions to be created.
We suggest that indicators require empirical evidence
of testing for key attributes such as acceptability and
feasibility before they can be safely used [5,6,31,32].
There are common attributes shared by indicator testing
protocols (Table 3). However, while the US HEDIS
Table 2 Indicators piloted and examples of issues raised as a result of piloting (Continued)
13 Palliative
Care
The percentage of patients on the palliative care
register who have a preferred place to receive end-of-
life care documented in the records
￿ Perceived potential harm to patients Acceptability:
preclude
￿ Changes to timing of which patients are put on the
register: the palliative care register is perceived to
often be quite subjective
Feasibility: no
barriers
￿ The indicator does not pro-actively encourage GPs
to keep the preferred place for end of care up to
date
Reliability: no
barriers
￿ Anxiety over the rigidity of the stipulated
timeframes which are too prescriptive
Implementation:
preclude
￿ Undue focus on one isolated question from a
mutlifaceted and complex issue
Overall: preclude
￿ Problems of attribution/not necessarily general
practice team’s responsibility
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Page 8 of 11methodology and QUALIFY [7] focus on the three key
concepts of relevance, scientific soundness and feasibil-
ity,[6] the AMA-PCIP protocol focuses on a wider range
of attributes over the short and long term [9]. In the US
agencies such as The National Quality Forum (NQF)
[33] and the National Quality Measure Clearinghouse
(NQMC) [34] have also proposed measure standards
but these have not been developed into a measure test-
ing protocol.
The indicator testing protocol we are advocating in this
paper codifies existing experience in this area and pro-
poses a testing protocol using a 6 month piloting time-
frame. It privileges implementation issues but places the
views of coal face practice staff at the centre of the piloting
process. The worth of a test piloting protocol is the overall
sum of its parts. The palliative care indicator reported in
this paper provides an exemplar of the importance of a
multiple attribute indicator testing protocol.
Conclusions
The UK government currently spends over 1 billion
pounds each year on QOF. Each UK pilot cost £150,000
(0.0005% of the overall cost). The act of piloting indicators
is therefore value for money as it identifies implementa-
tion issues of acceptability and unintended consequences
as well as technical reliability and feasibility that can be
addressed and rectified prior to national roll out. More-
over, it highlights indicators that should not be included.
An indicator testing protocol must act as a foundation
stone for the field testing and development of country
specific quality indicators for pay-for-performance or
quality improvement schemes. Local adaptations of this
protocol could be used by policy-makers and researchers
to empirically test the likely effect of implementing indi-
cators. Whilst national in scope, the lessons are, we
hope, therefore generalizable for an international
audience.
Appendix 1: Summary of indicator testing
protocol
Clarity
￿ The indicator wording is clear and precise with unam-
biguous language that reflects a specific domain of con-
tent, as rated by the RAND/UCLA Appropriateness
Method
￿ The indicator is within the control of the clinician/
practice, as rated by the RAND Appropriateness Method
Content validity
￿ The indicator statement represents high quality care
and is therefore a valid indicator of quality. There is suf-
ficient evidence/professional consensus to support it and
there are clear benefits to the patient receiving the care
(or the benefits significantly outweigh the risks).
◦ Each indicator is underpinned by a NICE/SIGN
guideline.
◦ Each indicator is rated necessary by a RAND
Appropriateness Method, which is based on physi-
cians/practice staff adhering to the indicator provid-
ing a higher quality of care/service than those who
are not doing so.
Technical feasibility and reliability of data extraction
￿ Ability to write and integrate data extraction specifica-
tions into health information systems from all family
practices
￿ Ability to generate reproducible test reports within a
reasonable time frame and budget from all family
practices
Acceptability
￿ Alignment to professional values and family practice
￿ Likely patient benefit
Implementation
￿ Discriminate validity: assessment of indicator to discri-
minate within a nationally representative sample of
family practices
Table 3 Attributes common to published indicator
testing protocols
UK-ITP
+ AMA-PCIP [10] NCQA/HEDIS
[6]
Qualify [7]
NICE prioritisation Needs
assessment
Relevance Relevance
Acceptability Acceptability
Clarity Clarity Precision = Clarity/
specificity
Feasibility Feasibility Feasibility Feasibility
Reliability Reliability Reproducibility~ Reliability~
Validity * Validity *# Validity * Validity *~
Implementation Implementation Implementation Implementation
-Unintended -Unintended -Controllability¬ -Risks/side
effects¬
Consequences Consequences -Benchmarking/ -Benchmarking/
-Benchmarking/ -Benchmarking
Sensitivity to
change
-Workload
Cost effectiveness Cost
effectiveness¬
+ UK-ITP: Indicator testing protocol described in this paper
Validity *: face and content validity underpinned by evidence based guideline
Validity#: predictive validity.
~ As part of Scientific Soundness.
¬ As part of Relevance.
= As part of Feasibility.
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Page 9 of 11￿ Sensitivity to change: assessment of current baseline
of the indicator and potential change in baseline at the
end of piloting
￿ Clinical practice staff are able to interpret the
indicator
￿ Potential for gaming/manipulation (exception
reporting)
￿ Changes required in practice organization to imple-
ment the indicator (i.e. acquisition and/or modification
of IT; changes in physical capital or staffing; changes to
practice policies and culture).
￿ Workload implications of implementing the indicator
￿ Potential barriers to the implementation of the
indicators
￿ Unintended consequences to the implementation of
the indicator: these can be positive or negative in nature
(i.e. disruption to clinical or organisational workflow,
‘spillovers’ that may be negative (diversion of effort) or
positive (encouraging general quality improvement).
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